Affordable Access

Access to the full text

Peanut Oral Immunotherapy: a Current Perspective

Authors
  • Patrawala, Meera1, 2
  • Shih, Jennifer1, 2
  • Lee, Gerald1, 2
  • Vickery, Brian2
  • 1 Emory University School of Medicine, 1400 Tullie Road NE 5th floor, Atlanta, GA, 30329, USA , Atlanta (United States)
  • 2 Children’s Healthcare of Atlanta, 1400 Tullie Road NE 5th floor, Atlanta, GA, 30329, USA , Atlanta (United States)
Type
Published Article
Journal
Current Allergy and Asthma Reports
Publisher
Springer-Verlag
Publication Date
Apr 20, 2020
Volume
20
Issue
5
Identifiers
DOI: 10.1007/s11882-020-00908-6
Source
Springer Nature
Keywords
License
Yellow

Abstract

Purpose of the ReviewPeanut oral immunotherapy (OIT) is one of the most studied experimental therapies for food allergy. With the recently FDA-approved peanut product, Palforzia, the goal of this article is to review the most recent data from clinical trials, discuss recent trends, and anticipate future developments.Recent FindingsThe latest research suggests that peanut OIT could be a promising option for peanut-allergic patients, with the majority of participants in research studies achieving the primary efficacy endpoint of desensitization, as well as sustained unresponsiveness in select populations. Some studies also showed improvements in food allergy-related quality of life. However, peanut OIT is not without risk or side effects, including potentially serious allergic reactions.SummaryFuture research will need to evaluate the short- and long-term effectiveness of the therapy in the real-world setting, predictors of important treatment outcomes, and the use of adjunctive therapies that may mitigate some of these allergic reactions.

Report this publication

Statistics

Seen <100 times